A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

Trial Profile

A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Acronyms ProPSMA
  • Most Recent Events

    • 20 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 04 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top